Information Provided By:
Fly News Breaks for June 6, 2018
TNXP
Jun 6, 2018 | 04:57 EDT
B. Riley FBR analyst David Buck started Tonix Pharmaceuticals with a Buy rating and $8 price target. The analyst sees an attractive risk/reward ahead of a potential near-term catalyst for the company's treatment of post-traumatic stress disorder.
News For TNXP From the Last 2 Days
There are no results for your query TNXP